ATE143598T1 - Arzneimittellösung enhaltend derivate von fk506 - Google Patents

Arzneimittellösung enhaltend derivate von fk506

Info

Publication number
ATE143598T1
ATE143598T1 AT91102996T AT91102996T ATE143598T1 AT E143598 T1 ATE143598 T1 AT E143598T1 AT 91102996 T AT91102996 T AT 91102996T AT 91102996 T AT91102996 T AT 91102996T AT E143598 T1 ATE143598 T1 AT E143598T1
Authority
AT
Austria
Prior art keywords
solution containing
medicinal solution
containing derivatives
derivatives
medicinal
Prior art date
Application number
AT91102996T
Other languages
English (en)
Inventor
Shigeo Nakanishi
Iwao Yamanaka
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of ATE143598T1 publication Critical patent/ATE143598T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
AT91102996T 1990-03-01 1991-02-28 Arzneimittellösung enhaltend derivate von fk506 ATE143598T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5111090 1990-03-01

Publications (1)

Publication Number Publication Date
ATE143598T1 true ATE143598T1 (de) 1996-10-15

Family

ID=12877668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91102996T ATE143598T1 (de) 1990-03-01 1991-02-28 Arzneimittellösung enhaltend derivate von fk506

Country Status (20)

Country Link
EP (1) EP0444659B1 (de)
JP (1) JP2522121B2 (de)
KR (1) KR0177158B1 (de)
CN (1) CN1028961C (de)
AT (1) ATE143598T1 (de)
AU (1) AU642707B2 (de)
CA (1) CA2037408C (de)
DE (1) DE69122418T2 (de)
DK (1) DK0444659T3 (de)
ES (1) ES2093650T3 (de)
GR (1) GR3021777T3 (de)
HK (1) HK62797A (de)
HU (2) HU209436B (de)
IE (1) IE75221B1 (de)
MX (1) MX9203032A (de)
PT (1) PT96916B (de)
RU (1) RU2028142C1 (de)
SG (1) SG47986A1 (de)
UA (1) UA51608C2 (de)
ZA (1) ZA911502B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
JPH07505628A (ja) * 1992-03-30 1995-06-22 アメリカン・ホーム・プロダクツ・コーポレイション 静脈注射用のラパマイシン製剤
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
RU2177783C1 (ru) * 2001-02-02 2002-01-10 Общество С Ограниченной Ответственностью "Консорциум-Пик" Ноотропное средство
RU2178292C1 (ru) * 2001-04-13 2002-01-20 Государственный научный центр колопроктологии Министерства здравоохранения и медицинской промышленности РФ Средство для общего промывания желудочно-кишечного тракта
US7402327B2 (en) * 2002-09-10 2008-07-22 Pepsico, Inc. Use of surfactants to solubilize water-insoluble solids in beverages
SI1663216T1 (sl) 2003-08-29 2012-03-30 Veloxis Pharmaceuticals As Sestavek z modificiranim sproščanjem ki vsebuje takrolimus
AU2004267909B2 (en) 2003-08-29 2008-12-18 Veloxis Pharmaceuticals, Inc. Modified release compositions comprising tacrolimus
CN1765365B (zh) * 2004-09-29 2012-01-25 天马药业(集团)股份有限公司 提高苷或苷元类药物在胃内吸收的口服软胶囊
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
FR2879932B1 (fr) * 2004-12-27 2007-03-23 Aventis Pharma Sa Formulations injectable ou administrable par voie orale de derives d'azetidine
SI2167033T1 (sl) 2007-05-30 2017-08-31 Veloxis Pharmaceuticals A/S Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
CL2008000374A1 (es) 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
CN101869547B (zh) 2009-04-24 2012-02-22 张娜 一种他克莫司注射制剂
LT2575769T (lt) 2010-02-17 2016-10-10 Veloxis Pharmaceuticals A/S Stabilizuota takrolimuzo kompozicija
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
CN115463097B (zh) * 2021-06-11 2024-04-19 杭州中美华东制药有限公司 一种他克莫司缓释中间体颗粒的制备工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430455D0 (en) * 1984-12-03 1985-01-09 Fujisawa Pharmaceutical Co Fr-900506 substance
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
CH677448A5 (de) * 1987-11-09 1991-05-31 Sandoz Ag
EP0350164A3 (de) * 1988-06-13 1991-07-24 Beecham Group Plc Amphotericin-Derivate

Also Published As

Publication number Publication date
CA2037408C (en) 2002-12-17
RU2028142C1 (ru) 1995-02-09
JP2522121B2 (ja) 1996-08-07
ES2093650T3 (es) 1997-01-01
CN1055110A (zh) 1991-10-09
KR910016336A (ko) 1991-11-05
DK0444659T3 (da) 1996-11-18
HU211502A9 (en) 1995-11-28
JPH04211012A (ja) 1992-08-03
EP0444659A3 (en) 1991-12-18
IE910679A1 (en) 1991-09-11
SG47986A1 (en) 1998-04-17
PT96916A (pt) 1991-11-29
AU642707B2 (en) 1993-10-28
GR3021777T3 (en) 1997-02-28
HU209436B (en) 1994-06-28
MX9203032A (es) 1992-07-31
HK62797A (en) 1997-05-16
ZA911502B (en) 1991-12-24
HUT57043A (en) 1991-11-28
UA51608C2 (uk) 2002-12-16
KR0177158B1 (ko) 1999-03-20
DE69122418T2 (de) 1997-03-06
EP0444659A2 (de) 1991-09-04
DE69122418D1 (de) 1996-11-07
EP0444659B1 (de) 1996-10-02
PT96916B (pt) 1998-07-31
IE75221B1 (en) 1997-08-27
AU7194991A (en) 1991-10-31
CA2037408A1 (en) 1991-09-02
CN1028961C (zh) 1995-06-21
HU910681D0 (en) 1991-09-30

Similar Documents

Publication Publication Date Title
ATE143598T1 (de) Arzneimittellösung enhaltend derivate von fk506
KR870700620A (ko) 신규 약리학적 화합물
NO180166C (no) Pyrrolidin- og tiazolidinderivater samt medikamenter inneholdende forbindelsene
ATE81009T1 (de) N-acetyl-3-fluoroneuraminsaeure als antivirales arzneimittel.
SE9100920D0 (sv) New active compounds
ATE92489T1 (de) Imid-derivate, ihre herstellung und verwendung.
NO881835D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive bicykliske forbindelser.
ES2106058T3 (es) Derivados de benzamida.
DK521685A (da) Spergualin-derivater og anvendelse deraf til fremstilling af laegemidler med immunosuppressiv virkning
FI911138A0 (fi) Ny substituerad aminfoerening och foerfarande foer dess framstaellning.
ATE86259T1 (de) Antibakterielle 9-deoxy-9a-allyl und propargyl-9a-aza-9a-homoerythromycin-a-derivate
DK0617959T3 (da) Lægemiddel til behandling af hudsygdomme
DK377687D0 (da) Triazol-fungicidpraeparater
FI904449A0 (fi) N-azasicyklo/3.3.0/oktanamider av aromatiska syror.
SE8503054D0 (sv) Catecholcarboxamides
DK656889A (da) Azabicykliske derivater
DK644487D0 (da) Farmaceutisk praeparat indeholdende en 2-oxo-imidazolidinforbindelse
FI933928A0 (fi) Heteroarenylpiperaziner, foerfarande foer framstaellning av dessa och anvaendning som laekemedel
DK653687A (da) Middel til behandling af nyresygdomme
ATE201023T1 (de) Ellipticinederivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time